Real-word evidence in anti-VEGF naive patients treated with pazopanib for metastatic renal cell carcinoma (mRCC), the APOLON Study.

Fiche publication

Date publication

septembre 2025

Journal

ESMO real world data and digital oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe , Dr LONGO Raffaele , Dr THIERY-VUILLEMIN Antoine

Tous les auteurs :
Barthelemy P, Thiery-Vuillemin A, Lebret T, Bigot P, Stein U, Dourthe LM, Longo R, Gimel P, Auberger B, De La Cruz J, Malak D, Samia Z, Texier N, Albiges L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41646210

Résumé

Immune checkpoint inhibitor-based combinations have become the standard of care for treatment-naive metastatic renal cell carcinoma mRCC). Tyrosine kinase inhibitor (TKI) monotherapy, however, may remain an option particularly for patients with a favourable International Metastatic Database Consortium (IMDC) risk.